Lung cancer: open trials in Canada

156 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
Jewish General Hospital, Montreal · Ottawa Hospital Regional Cancer Centre, Ottawa · Princess Margaret Cancer Center, Toronto
Registry updated 2026-11-05
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
Royal Victoria Regional Health Centre, Barrie · William Osler Health Centre - Brampton Civic Hospital, Brampton · BC Cancer ? Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna · Jewish General Hospital, Montreal · Ottawa Hospital Research Institute, Ottawa · CHU de Quebec - Hôpital de l' Enfant Jésus, Québec · Centre Hospitalier Regional De Rimouski, Rimouski · Saskatoon Cancer Centre, Saskatoon · BC Cancer - Victoria, Victoria
Registry updated 2026-11-05
NCT06882174
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
Trial Treatment · Phase 2 · AHS Cancer Control Alberta
Cross Cancer Institute, Edmonton
Registry updated 2026-11-05
NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Trial Treatment · Phase 1 · Pfizer
McGill University Health Centre, Montreal · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-05
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Pfizer
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Sante Quebec Monteregie-Centre, Greenfield Park · Sante Quebec Laval, Hopital de la Cite-de-la-Sante, Laval · McGill University Health Centre, Montreal · Lakeridge Health, Oshawa · IUCPQ-Universite Laval, Québec · Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Québec · Unité de Recherche Clinique du CISSS des Laurentides, Saint-Jérôme · Centre de Services Ambulatoire de St-Jerome, Saint-Jérôme · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
St. Marys Hospital Center, Montreal · The Ottawa Hospital - General Campus, Ottawa · IUCPQ, Québec
Registry updated 2026-11-05
NCT07920549
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer
Trial Treatment · Phase 2/3 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
London Health Sciences Centre - Verspeeten Family Cancer Centre, London
Registry updated 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
BC Cancer Abbotsford, Abbotsford British Columbia · CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi · BC Cancer - Vancouver, Vancouver
Registry updated 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Brampton Civic Hospital | Oncology, Brampton · Jewish General Hospital | Pulmonary Oncology, Montreal · Princess Margaret Cancer Centre | Medical Oncology and Hematology, Toronto · BC Cancer - Vancouver, Vancouver
Registry updated 2026-11-04
NCT06706076
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Trial Treatment · Phase 1/2 · BlossomHill Therapeutics
Cross Cancer Institute, Edmonton · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-04
NCT06813664
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
Trial Treatment · Phase 2 · University Health Network, Toronto
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto
Registry updated 2026-11-04
NCT07492680
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Trial Treatment · Phase 2 · Bristol-Myers Squibb
Toronto · Toronto · Vancouver
Registry updated 2026-11-04
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Toronto
Registry updated 2026-11-03
NCT04952480
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Trial Treatment · Phase 2 · AHS Cancer Control Alberta
Cross Cancer Institute, Edmonton
Registry updated 2026-11-03
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
William Osler Health System ( Site 0203), Brampton · Trillium Health Partners - Credit Valley Hospital ( Site 0202), Mississauga · McGill University Health Centre ( Site 0200), Montreal
Registry updated 2026-11-03
NCT07227025
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Trial Treatment · Phase 1/2 · Janssen Research & Development, LLC
Princess Margaret Hospital, Toronto
Registry updated 2026-11-03
NCT07586202
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Princess Margaret Hospital, Toronto
Registry updated 2026-11-03
NCT07660055
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Trial Treatment · Phase 1 · Novartis Pharmaceuticals
Montreal
Registry updated 2026-11-03
NCT07699328
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 1/2 · Voronoi, Inc
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-03
NCT06745908
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Trial Treatment · Phase 3 · ImmunityBio, Inc.
William Osler Health System - Brampton Civic Hospital, Brampton · Waterloo Regional Health Network - Midtown, Kitchener · London Health Sciences Centre - Verspeeten Family Cancer Centre, London · Southlake Regional Health Centre, Newmarket · Vancouver Coastal Health, North Vancouver · Horizon Health Network - Saint John Regional Hospital (SJRH), Saint John · University of Windsor, Windsor
Registry updated 2026-11-02
NCT07166601
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Trial Treatment · Phase 1 · EMD Serono Research & Development Institute, Inc.
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-02
NCT07185997
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Trial Treatment · Phase 3 · ArriVent BioPharma, Inc.
Brampton Civic Hospital, William Osler Health Centre, Brampton · Alberta Health Services, Tom Baker Cancer Centre, Calgary · University of Alberta - Cross Cancer Institute (CCI), Edmonton · The Ottawa Hospital Cancer Centre, Ottawa · Sunnybrook Research Institute, Toronto · Princess Margaret Cancer Centre - University Health Network, Toronto · BC Cancer Vancouver Centre, Vancouver
Registry updated 2026-11-02
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Trial Treatment · Phase 3 · Boehringer Ingelheim
Cross Cancer Institute (University of Alberta), Edmonton · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-02
NCT07431827
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
CIUSSS- saguenay-Lac-Saint-Jean ( Site 0216), Chicoutimi · Moncton Hospital ( Site 0200), Moncton · Centre Hospitalier de l'Université de Montréal ( Site 0219), Montreal
Registry updated 2026-11-02
NCT07910942
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
Trial Treatment · Phase 1 · Kanvas Biosciences
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal
Registry updated 2026-11-02

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error